103 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
9 May 24
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
7:36pm
, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
ages and 7% in those over 30 years of age. The mean age of death reported from a 40-year mortality study in the U.S. was 29.5 ± 15 years (range: 2
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
% in those over 30 years of age. The mean age of death reported from a 40-year mortality study in the U.S. was 29.5 ± 15 years (range: 2 months—67 years
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey
8-K
EX-99.1
nnu4u
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
8-K
EX-10.1
e5vuftv0pb3bzwvwh b6
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
424B5
3c6pd3m42jl3mog2c2
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
n4l wska82zu5
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
vvpvi h5p2ycx5g4
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
l4ce80 hk0zw6earlw1
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
d72udgutdst8 sgs
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
jaqsx48pi 1ikl
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
ggael3f620y5k51ctny
3 May 23
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5:26pm
8-K
EX-99.1
sskoxbx dghd
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
x0aq5g wt73l6
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm